CAPN10 genetic variations influence the pharmacodynamic responses to diabetes medications like metformin, where these variations affect how the drug improves insulin sensitivity and overall therapeutic effectiveness. Similarly, CAPN10 interactions with tacrolimus could alter glucose metabolism in patients, indicating that this gene modifies how these drugs impact metabolic processes and clinical outcomes.